ANGO ANGIODYNAMICS INC

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: design, manufacture, and sale of innovative medical devices for cardiovascular disease and cancer treatment
• • New product emphasis: expanded FDA clearance for NanoKnife System prostate tissue ablation in Dec 2024 and MDR CE mark in Feb 2026 for multiple tumor ablations
• • Strategic shift: divestiture of dialysis, BioSentry (June 2023), and PICC/Midline businesses (Feb 2024); discontinuation of RadioFrequency Ablation and Syntrax lines
• • Quantitative metric: workforce reduced to approximately 632 full-time employees as of May 31, 2026
• • Noteworthy fact: ongoing regulatory challenges delaying FDA clearances amid increased testing requirements and expanded MDR compliance through 2027-2028

Risk Factors

• • Regulatory risk: FDA increased scrutiny on Quality System Regulation compliance and post-market requirements following July 2025 enactment of the One Big Beautiful Bill Act
• • Geopolitical risk: $0.7M revenue exposed to Iran distributors amid U.S. sanctions and rising Middle East conflicts impacting global trade and tariffs
• • Supply chain vulnerability: Transition of manufacturing to third-party sites in U.S., Costa Rica, Latvia, Italy, Israel, China by Q1 FY2027 with risk of disruptions and increased costs
• • Competitive risk: Price competition intensified by growing purchasing power of GPOs and IDNs, risking contract losses and reduced profitability
• • Financial risk: CEO transition planned by Nov 2026 poses leadership uncertainty potentially impacting operations and investor confidence

Management Discussion & Analysis

• • Revenue $320.2M, up 9.5% YoY ($292.5M in FY 2025); Med Tech grew 18.4% ($150.0M) strongest, Med Device up 2.6% ($170.2M)
• • Gross margin 54.6% vs 53.9% YoY; Med Tech margin 63.6% vs 62.0%, Med Device margin declined 46.7% vs 47.7%
• • Net loss increased to $36.7M from $34.0M; loss per share widened to $0.88 from $0.83
• • Operating cash flow positive $3.1M vs negative $10.1M prior year; capex $2.6M plus $3.4M on unit placements; $1.7M stock buybacks in FY 2025, none in FY 2026
• • Management pursuing restructuring to save $15M annually by FY 2027; share repurchase authorization $15M with $13.3M remaining; key risks include inflation, tariffs, supply chain disruptions

What are the latest ANGO SEC filings in 2026?

ANGIODYNAMICS INC (ANGO) has filed a 10-K annual report on July 14, 2026, a 10-Q quarterly report on April 2, 2026, an 8-K current report on July 14, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ANGO file its most recent 10-K annual report?

ANGIODYNAMICS INC (ANGO) filed its most recent 10-K annual report on July 14, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ANGO 10-Q quarterly reports?

ANGIODYNAMICS INC (ANGO)'s most recent 10-Q quarterly report was filed on April 2, 2026. SignalX displays every ANGO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ANGO filed recently?

ANGIODYNAMICS INC (ANGO)'s most recent 8-K was filed on July 14, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ANGO insider trading activity (Form 4)?

SignalX aggregates every ANGO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ANGO file with the SEC?

ANGIODYNAMICS INC (ANGO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ANGO filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ANGIODYNAMICS INC (ANGO).

What is ANGO's SEC CIK number?

ANGIODYNAMICS INC (ANGO)'s SEC CIK (Central Index Key) number is 1275187. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1275187 to look up all ANGO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ANGO return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from ANGIODYNAMICS INC (ANGO) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.